MustGrow Biologics Corp. Announces Results of Shareholder Meeting

Rhea-AI Summary

MustGrow Biologics (OTCQB:MGROF) held its 2025 annual shareholder meeting on June 26, 2025, where all proposed directors were successfully elected with strong shareholder support. Each director received over 95% approval, with most garnering more than 99% of votes.

Shareholders also approved the reappointment of Ernst & Young LLP as auditors and reapproved the company's omnibus equity incentive plan, which remains subject to final TSX Venture Exchange approval.

Saskatoon, Saskatchewan--(Newsfile Corp. - June 26, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce the results of its 2025 annual meeting of shareholders (the "Meeting") held on June 26, 2025. At the Meeting, all director nominees listed in the Company's management information circular dated May 28, 2025 were elected by shareholders as directors of the Company on a vote held by ballot. The results of the ballot were as follows:

Director	Vote Type	Number of Votes	Percentage of Votes
Corey Giasson	For	6,180,855	99.66%
	Withheld	21,200	0.34%
Colin Bletsky	For	6,180,855	99.66%
	Withheld	21,200	0.34%
Brad Munro	For	6,180,855	99.66%
	Withheld	21,200	0.34%
Thomas Flow	For	5,942,855	95.82%
	Withheld	259,200	4.18%
Matt Kowalski	For	6,183,705	99.70%
	Withheld	18,350	0.30%
David Borecky	For	5,941,705	95.80%
	Withheld	260,350	4.20%
Laura Westby	For	6,179,705	99.64%
	Withheld	22,350	0.36%

 

In addition, shareholders approved the reappointment of Ersnt & Young LLP, Chartered Professional Accountants, as the Company's auditors and authorized the directors of the Company to fix their remuneration, and reapproved the Company's omnibus equity incentive plan (the "Omnibus Plan"). Having received shareholder approval, the Company's Omnibus Plan remains subject to final approval from the TSX Venture Exchange.

The formal report on voting results with respect to all matters voted upon at the Meeting will be filed on SEDAR+ under the Company's profile at www.sedarplus.ca.

About MustGrow

MustGrow Biologics Corp. is a fully-integrated provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company's proprietary and third-party product lines offer eco-friendly alternatives to restricted or banned synthetic chemicals and fertilizers. In North America, MustGrow offers a portfolio of third-party crop nutrition solutions, including micronutrients, nitrogen stabilizers, biostimulants, adjuvants and foliar products. These products are synergistically distributed alongside MustGrow's wholly-owned proprietary products and technologies that are derived from mustard and developed into organic biocontrol and biofertility products to help replace banned or restricted synthetic chemicals and fertilizers. Outside of North America, MustGrow is focused on collaborating with agriculture companies, such as Bayer AG in Europe, the Middle East and Africa, to commercialize MustGrow's wholly-owned proprietary products and technologies. The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio of approximately 112 patents that are currently issued and pending, and the sales and distribution of its proprietary and third-party product lines through NexusBioAg. MustGrow is a publicly traded company (TSXV: MGRO) and has approximately 52.4 million common shares issued and outstanding and 59.4 million shares fully diluted. For further details, please visit www.mustgrow.ca.

Contact Information

Corey Giasson Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca

MustGrow Forward-Looking Statements

Certain statements included in this news release constitute "forward-looking statements" which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.

Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", "is expected", "budget", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "occur" or "be achieved". Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow's actual results and financial condition to differ materially from those indicated in the forward-looking statements include: the receipt of final approval by the TSXV and those risks described in more detail in MustGrow's Annual Information Form for the year ended December 31, 2024 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on SEDAR+ at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.

Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.

© 2025 MustGrow Biologics Corp. All rights reserved.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/257036

FAQ

What were the voting results for MustGrow Biologics (MGROF) 2025 shareholder meeting?

All director nominees were elected with strong support, receiving over 95% approval. Most directors received more than 99% of votes in favor.

Who are the directors elected to MustGrow Biologics' board in 2025?

The elected directors are Corey Giasson, Colin Bletsky, Brad Munro, Thomas Flow, Matt Kowalski, David Borecky, and Laura Westby.

What other matters were approved at MustGrow Biologics' 2025 annual meeting?

Shareholders approved the reappointment of Ernst & Young LLP as auditors and reapproved the company's omnibus equity incentive plan, pending TSX Venture Exchange final approval.

What was the lowest approval rating among MustGrow Biologics' director nominees?

David Borecky received the lowest approval rating at 95.80%, with Thomas Flow close at 95.82%, though both still represent strong shareholder support.